LUXEMBOURG / Feb 04, 2025 / Business Wire / Auna S.A. (NYSE: AUNA) (“Auna” or “the Company”), a leading Latin American healthcare services and plan provider with operations in Mexico, Peru and Colombia, announced today the reporting dates for its Fourth Quarter and Full-Year 2024 financial results.
Earnings Release
Monday, March 10, 2025
Time: After Market Close
Conference Call
Tuesday, March 11, 2025
Time: 8:00 a.m. ET
Quiet Period
Monday, February 17 through Monday, March 10, 2025
To participate, please dial
+1 888 596 4144 (Toll-Free)
+1 646 968 2525 (International)
Entry Passcode: 3884034
Webcast: click here
About Auna
Auna is a leading horizontally and vertically integrated healthcare platform in Latin America with operations in Mexico, Peru, and Colombia, focusing on high-complexity diseases. Our mission is to transform healthcare by providing access to a highly integrated healthcare offering in the underpenetrated markets of Spanish-speaking Americas. Founded in 1989, Auna has built one of Latin America′s largest modern healthcare platforms that consists of a horizontally integrated network of healthcare facilities and a vertically integrated portfolio of oncological plans and selected general healthcare plans. As of September 30, 2024, Auna’s network included 31 healthcare network facilities, including hospitals, outpatient, prevention and wellness facilities with 2,308 beds, and 1.3 million healthcare plans.
For more information visit www.aunainvestors.com
Last Trade: | US$6.50 |
Daily Change: | -0.06 -0.91 |
Daily Volume: | 11,230 |
Market Cap: | US$195.000M |
May 20, 2025 March 10, 2025 March 07, 2025 November 19, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load